Safety and Efficacy of Liraglutide in Combination With an OAD in Subjects With Type 2 Diabetes Insufficiently Controlled on OAD Alone

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 363 participants.

Also called NCT01512108

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; no masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 363 participants (enrolled count) (from the registry)
Sponsor
  • Novo Nordisk Registry lists this organization as the lead sponsor
Registry
  • NCT NCT01512108
Main results
  • Liraglutide is effective and well tolerated in combination with an oral antidiabetic drug in Japanese patients with type 2 diabetes: A randomized, 52-week, open-label, parallel-group trial Journal of diabetes investigation, 2016-01 DOI, PubMed 26816604, PMC4718097 PubMed links an erratum for this paper. Erratum: PMID 27042283 In the PMC Open Access subset under CC BY-NC-ND.
Other papers using this trial's data
  • Safety and efficacy of the combination of the glucagon-like peptide-1 receptor agonist liraglutide with an oral antidiabetic drug in Japanese patients with type 2 diabetes: Post-hoc analysis of a randomized, 52-week, open-label, parallel-group trial Journal of diabetes investigation, 2018-07 DOI, PubMed 28984041, PMC6031500 In the PMC Open Access subset under CC BY-NC.

Courtesy of the U.S. National Library of Medicine.

Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
Japan (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT01512108. Randomized; no masking; primary purpose treatment. Start 2012-01-10 (actual); primary completion 2013-04-26 (actual). Results posted on 2014-05-28.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Safety and Efficacy of Liraglutide in Combination With an OAD in Subjects With Type 2 Diabetes Insufficiently Controlled on OAD Alone
Condition
Diabetes
Condition
Diabetes Mellitus, Type 2
Intervention (Drug)
liraglutide
Intervention (Drug)
oral anti-diabetic drug
Lead sponsor
Novo Nordisk A/S (class: industry)

Record details

Record id
cardio:ct-nct01512108
Content hash
f671fad228b45cb86fd3c8512256c30ce6582c8100a0af827e39477399d59069